Cover Image
市場調查報告書

全球癌症疫苗市場分析、預測:樹突狀細胞癌症疫苗、重組癌症疫苗、抗原/佐劑癌症疫苗、全細胞癌症疫苗、病毒媒介 & DNA癌症疫苗

Cancer Vaccines Market by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, and others), Type, Indication, and End Use - Global Opportunity Analysis and Industry Forecast, 2017-2023

出版商 Allied Market Research 商品編碼 539656
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症疫苗市場分析、預測:樹突狀細胞癌症疫苗、重組癌症疫苗、抗原/佐劑癌症疫苗、全細胞癌症疫苗、病毒媒介 & DNA癌症疫苗 Cancer Vaccines Market by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, and others), Type, Indication, and End Use - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日期: 2017年07月01日 內容資訊: 英文 190 Pages
簡介

本報告提供全球癌症疫苗市場相關調查分析,市場概要,各技術、種類、適應症、終端用戶、地區的考察,並提供主要企業簡介等資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 波特的五力分析
  • 法律規範
  • 市場佔有率分析
  • 市場動態
    • 促進要素
    • 抑制因素
    • 機會

第4章 癌症疫苗市場:各技術

  • 概要
  • 樹突狀細胞癌症疫苗
  • 重組癌症疫苗
  • 抗原/佐劑癌症疫苗
  • 全細胞癌症疫苗
  • 病毒媒介、DNA癌症疫苗

第5章 癌症疫苗市場:各類型

  • 概要
    • 市場規模、預測
  • 預防癌症疫苗市場
    • 市場規模、預測
  • 治療癌症疫苗市場
    • 市場規模、預測

第6章 癌症疫苗:各適應症

  • 概要
    • 市場規模、預測
  • 子宮頸癌
  • 前列腺癌
  • 其他的適應症

第7章 癌症疫苗市場:各最終用途

  • 概要
  • 兒童
  • 成人

第8章 癌症疫苗市場:各地區

  • 概要
    • 市場規模、預測
  • 北美
    • 主要的市場趨勢
    • 主要的成長要素、機會
    • 市場規模、預測
  • 歐洲
  • 亞太地區
  • LAMEA (南美、中東、非洲)

第9章 企業簡介

目錄
Product Code: LI 171453

A vaccine is a biological preparation that strengthens the immune system and provides acquired immunity against a specific pathogen. According to the World Health Organization (WHO), cancer vaccines are popularly for treating various types of cancer such as, breast cancer, lung cancer, cervical cancer, and others. The key factors that driving the market growth include rise in prevalence of human papilloma virus (HPV) infections leading to cancers, increase in administration of prophylactic cancer vaccines, surge in investments in the development of cancer vaccines by manufacturers & governmental funding, and launch & approval of novel cancer vaccines in the market. The global cancer vaccines market was valued at $4,073 million in 2016, and is expected to reach at $12,814 million by 2023, registering a CAGR of 17.7% from 2017 to 2023.

The global cancer vaccines market is segmented based on technology, indication, type end use, and region. Based on technology, it is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, and viral vector & DNA cancer vaccines. Based on indication, it is bifurcated into cervical cancer, prostate cancer, and others. On the basis of end use, it is classified into pediatric vaccines and adult vaccines. Based on type, the market is divided into therapeutic cancer vaccines and preventive cancer vaccines.

Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain its dominance throughout the forecast period. This is attributed to the increase in prevalence of cervical cancers, rise in government focus on immunization programs, emergence of new vaccines, and growth in technological advancements in vaccine administration. However, Asia-Pacific is expected to witness maximum growth potential, due to the improvement in healthcare facilities, high disposable income, and rapid development of economic conditions.

KEY BENEFITS

  • The study provides an in-depth analysis of the global cancer vaccines market with current trends and future estimations to elucidate the imminent investment pockets.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry to understand the type of products and technologies used globally.
  • Key market players and their strategies are provided to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

BY TECHNOLOGY

  • Dendritic Cells (DC) Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Whole Cell Cancer Vaccines
  • Viral Vector & DNA Cancer Vaccines

BY TYPE

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines

BY INDICATION

  • Cervical Cancer
  • Prostate Cancer
  • Others

BY END USE

  • Pediatrics
  • Adults

BY REGION

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Argentina
  • Turkey
  • South Africa
  • Rest of LAMEA

KEY PLAYERS PROFILED

  • AstraZeneca PLC. (Medimmune, LLC.)
  • Glaxosmithkline Plc.
  • Merck & Co., Inc.
  • Sanofi Pasteur
  • Aduro BioTech Inc.
  • Astellas Pharma Inc.
  • CSL Limited
  • Pfizer Inc.
  • Sanpower Group
  • Serum Institute of India Pvt. Ltd.
  • The other players in the value chain include (profiles not included in the report)
  • Gritstone Oncology
  • PaxVax Corporation.
  • Bavarian Nordic
  • Bharat Biotech.
  • VBI Vaccines Inc.
  • Novavax, Inc.
  • Dynavax Technologies Corporation
  • Immunomic Therapeutics, Inc.
  • Gamma Vaccines Pty Limited
  • Sinovac Biotech Ltd.
  • Prokarium
  • ImmunoBiology Ltd.
  • Galena Biopharma

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENTS
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PORTERS FIVE FORCES ANALYSIS
  • 3.4. REGULATORY FRAMEWORK
  • 3.5. MARKET SHARE ANALYSIS, 2016
  • 3.6. MARKET DYNAMICS
    • 3.6.1. Drivers
      • 3.6.1.1. Rising prevalence of human papilloma virus (HPV) infections, causing cancers
      • 3.6.1.2. Increasing administration of prophylactic cancer vaccines
      • 3.6.1.3. Rising investments and government funding in the development of cancer vaccines
      • 3.6.1.4. Launch and approval of new cancer vaccines in the market
    • 3.6.2. Restraints
      • 3.6.2.1. High cost for development of cancer vaccines due to the need of frequent upgradation in manufacturing technology
      • 3.6.2.2. Longer timelines required for manufacturing a single vaccine
    • 3.6.3. Opportunities
      • 3.6.3.1. Increasing transition from prophylactic to therapeutic cancer vaccines
      • 3.6.3.2. High growth prospects in emerging markets

CHAPTER 4 CANCER VACCINES MARKET, BY TECHNOLOGY

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. DENDRITIC CELLS CANCER VACCINES
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. RECOMBINANT CANCER VACCINES
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. ANTIGEN/ADJUVANT CANCER VACCINES
    • 4.4.1. Key market trends
    • 4.4.2. Growth factors and opportunities
    • 4.4.3. Market size and forecast
  • 4.5. WHOLE CELL CANCER VACCINES
    • 4.5.1. Key market trends
    • 4.5.2. Growth factors and opportunities
    • 4.5.3. Market size and forecast
  • 4.6. VIRAL VECTOR AND DNA CANCER VACCINES
    • 4.6.1. Key market trends
    • 4.6.2. Growth factors and opportunities
    • 4.6.3. Market size and forecast

CHAPTER 5 CANCER VACCINES MARKET, BY TYPE

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. PREVENTIVE CANCER VACCINES
    • 5.2.1. Market size and forecast
  • 5.3. THERAPEUTIC CANCER VACCINES
    • 5.3.1. Market size and forecast

CHAPTER 6 CANCER VACCINES, BY INDICATION

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. CERVICAL CANCER
    • 6.2.1. Market size and forecast
  • 6.3. PROSTATE CANCER
    • 6.3.1. Market size and forecast
  • 6.4. OTHER INDICATIONS
    • 6.4.1. Market size and forecast

CHAPTER 7 CANCER VACCINES MARKET, BY END USE

  • 7.1. OVERVIEW
    • 7.1.1. Market size and forecast
  • 7.2. PEDIATRICS
    • 7.2.1. Market size and forecast
  • 7.3. ADULTS
    • 7.3.1. Market size and forecast

CHAPTER 8 CANCER VACCINES MARKET, BY GEOGRAPHY

  • 8.1. OVERVIEW
    • 8.1.1. Market size and forecast
  • 8.2. NORTH AMERICA
    • 8.2.1. Key market trends
    • 8.2.2. Key growth factors and opportunities
    • 8.2.3. Market size and forecast
      • 8.2.3.1. U.S. market size and forecast
      • 8.2.3.2. Mexico market size and forecast
      • 8.2.3.3. Canada market size and forecast
  • 8.3. EUROPE
    • 8.3.1. Key market trends
    • 8.3.2. Key growth factors and opportunities
    • 8.3.3. Market size and forecast
      • 8.3.3.1. UK market size and forecast
      • 8.3.3.2. France market size and forecast
      • 8.3.3.3. Germany market size and forecast
      • 8.3.3.4. Italy market size and forecast
      • 8.3.3.5. Spain market size and forecast
      • 8.3.3.6. Rest of Europe market size and forecast
  • 8.4. ASIA-PACIFIC
    • 8.4.1. Key market trends
    • 8.4.2. Key growth factors and opportunities
    • 8.4.3. Market size and forecast
      • 8.4.3.1. Japan market size and forecast
      • 8.4.3.2. China market size and forecast
      • 8.4.3.3. India market size and forecast
      • 8.4.3.4. Australia market size and forecast
      • 8.4.3.5. Rest of Asia-Pacific market size and forecast
  • 8.5. LAMEA
    • 8.5.1. Key market trends
    • 8.5.2. Key growth factors and opportunities
    • 8.5.3. Market size and forecast
      • 8.5.3.1. Brazil market size and forecast
      • 8.5.3.2. Argentina market size and forecast
      • 8.5.3.3. Turkey market size and forecast
      • 8.5.3.4. South Africa market size and forecast
      • 8.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 9 COMPANY PROFILES

  • 9.1. ASTRAZENECA PLC. (MEDIMMUNE, LLC.)
    • 9.1.1. Company overview
    • 9.1.2. Company snapshot
    • 9.1.3. Operating business segments
    • 9.1.4. Business performance
    • 9.1.5. Key strategic moves and developments
  • 9.2. GLAXOSMITHKLINE PLC.
    • 9.2.1. Company overview
    • 9.2.2. Company snapshot
    • 9.2.3. Operating business segments
    • 9.2.4. Business performance
    • 9.2.5. Key strategic moves and developments
  • 9.3. MERCK & CO., INC.
    • 9.3.1. Company overview
    • 9.3.2. Company snapshot
    • 9.3.3. Operating business segments
    • 9.3.4. Business performance
    • 9.3.5. Key strategic moves and developments
  • 9.4. SANOFI PASTEUR
    • 9.4.1. Company overview
    • 9.4.2. Company snapshot
    • 9.4.3. Operating business segments
    • 9.4.4. Business performance
    • 9.4.5. Key strategic moves and developments
  • 9.5. ADURO BIOTECH INC.
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Operating business segments
    • 9.5.4. Business performance
    • 9.5.5. Key strategic moves and developments
  • 9.6. SANPOWER GROUP CO., LTD.
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Operating business segments
    • 9.6.4. Business performance
    • 9.6.5. Key strategic moves and developments
  • 9.7. ASTELLAS PHARMA INC.
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Operating business segments
    • 9.7.4. Business performance
    • 9.7.5. Key strategic moves and developments
  • 9.8. CSL LIMITED
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Operating business segments
    • 9.8.4. Business performance
    • 9.8.5. Key strategic moves and developments
  • 9.9. PFIZER INC.
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Operating business segments
    • 9.9.4. Business performance
    • 9.9.5. Key strategic moves and developments
  • 9.10. SERUM INSTITUTE OF INDIA PVT. LTD.
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Operating business segments
    • 9.10.4. Business performance
    • 9.10.5. Key strategic moves and developments

List of Tables

  • TABLE 1. GLOBAL CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 2. GLOBAL DENDRITIC CELLS CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 3. GLOBAL RECOMBINANT CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 4. GLOBAL ANTIGEN/ADJUVANT CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 5. GLOBAL WHOLE CELL CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 6. GLOBAL VIRAL VECTOR AND DNA CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 7. GLOBAL CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 8. GLOBAL PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 10. GLOBAL CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 11. GLOBAL CANCER VACCINES MARKET FOR CERVICAL CANCER, BY REGION, 2016-2023 ($MILLION)
  • TABLE 12. GLOBAL CANCER VACCINES MARKET FOR PROSTATE CANCER, BY REGION, 2016-2023 ($MILLION)
  • TABLE 13. GLOBAL CANCER VACCINES MARKET FOR OTHER INDICATIONS BY REGION, 2016-2023 ($MILLION)
  • TABLE 14. GLOBAL CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
  • TABLE 15. GLOBAL CANCER VACCINES MARKET FOR PEDIATRICS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 16. GLOBAL CANCER VACCINES MARKET FOR ADULTS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 17. GLOBAL CANCER VACCINES MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 18. NORTH AMERICA CANCER VACCINES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 19. NORTH AMERICA CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 20. NORTH AMERICA CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 21. NORTH AMERICA CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 22. NORTH AMERICA CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
  • TABLE 23. EUROPE CANCER VACCINES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 24. EUROPE CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 25. EUROPE CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 26. EUROPE CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 27. EUROPE CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
  • TABLE 28. ASIA-PACIFIC CANCER VACCINES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 29. ASIA-PACIFIC CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 30. ASIA-PACIFIC CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 31. ASIA-PACIFIC CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 32. ASIA-PACIFIC CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
  • TABLE 33. LAMEA CANCER VACCINES MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 34. LAMEA CANCER VACCINES MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
  • TABLE 35. LAMEA CANCER VACCINES MARKET, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 36. LAMEA CANCER VACCINES MARKET, BY INDICATION, 2016-2023 ($MILLION)
  • TABLE 37. LAMEA CANCER VACCINES MARKET, BY END USE, 2016-2023 ($MILLION)
  • TABLE 38. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 39. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 40. GSK: COMPANY SNAPSHOT
  • TABLE 41. GSK: OPERATING SEGMENTS
  • TABLE 42. MERCK: COMPANY SNAPSHOT
  • TABLE 43. MERCK: OPERATING SEGMENTS
  • TABLE 44. SANOFI: COMPANY SNAPSHOT
  • TABLE 45. SANOFI: OPERATING SEGMENTS
  • TABLE 46. ADURO: COMPANY SNAPSHOT
  • TABLE 47. ADURO: OPERATING SEGMENTS
  • TABLE 48. SANPOWER: COMPANY SNAPSHOT
  • TABLE 49. SANPOWER: OPERATING SEGMENTS
  • TABLE 50. ASTELLAS: COMPANY SNAPSHOT
  • TABLE 51. ASTELLAS: OPERATING SEGMENTS
  • TABLE 52. CSL: COMPANY SNAPSHOT
  • TABLE 53. CSL: OPERATING SEGMENTS
  • TABLE 54. PFIZER: COMPANY SNAPSHOT
  • TABLE 55. PFIZER: OPERATING SEGMENTS
  • TABLE 56. SERUM: COMPANY SNAPSHOT
  • TABLE 57. SERUM: OPERATING SEGMENTS

List of Figures

  • FIGURE 1. GLOBAL CANCER VACCINES MARKET, 2016-2023
  • FIGURE 2. SEGMENTATION OF CANCER VACCINES MARKET
  • FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL CANCER VACCINES MARKET
  • FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
  • FIGURE 5. TOP WINNING STRATEGIES: NATURE AND TYPE
  • FIGURE 6. TOP WINNING STRATEGIES: NATURE AND COMPANY
  • FIGURE 7. BARGAINING POWER OF BUYERS
  • FIGURE 8. BARGAINING POWER OF SUPPLIERS
  • FIGURE 9. THREAT OF NEW ENTRANTS
  • FIGURE 10. THREAT OF SUBSTITUTION
  • FIGURE 11. COMPETITIVE RIVALRY
  • FIGURE 12. RESTRAINTS AND DRIVERS: GLOBAL CANCER VACCINES MARKET
  • FIGURE 13. U.S. CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 14. MEXICO CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 15. CANADA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 16. UK CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 17. FRANCE CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 18. GERMANY CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 19. ITALY CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 20. SPAIN CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 21. REST OF EUROPE CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 22. JAPAN CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 23. CHINA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 24. INDIA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 25. AUSTRALIA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 26. REST OF ASIA-PACIFIC CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 27. BRAZIL CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 28. ARGENTINA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 29. TURKEY CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 30. SOUTH AFRICA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 31. REST OF LAMEA CANCER VACCINES MARKET, 2016-2023 ($MILLION)
  • FIGURE 32. ASTRAZENECA: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 33. ASTRAZENECA: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 34. ASTRAZENECA: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 35. GSK: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 36. GSK: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 37. GSK: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 38. MERCK: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 39. MERCK: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 40. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 41. SANOFI: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 42. SANOFI: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 43. SANOFI: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 44. ADURO: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 45. ADURO: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 46. ADURO: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 47. SANPOWER: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 48. SANPOWER: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 49. SANPOWER: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 50. ASTELLAS: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 51. ASTELLAS: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 52. ASTELLAS: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 53. CSL: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 54. CSL: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 55. CSL: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 56. PFIZER: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 57. PFIZER: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 58. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 59. SERUM: NET SALES, 2014-2016 ($MILLION)
  • FIGURE 60. SERUM: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 61. SERUM: REVENUE BY GEOGRAPHY, 2016 (%)
Back to Top